Effectiveness evaluation
cough, Depression, Cough, Anxiety
ADVERSE EVENTS, EVENTS, EVENTS
Clinical data will be recorded during the lead-in period before randomization. The objective cough frequency, cough VAS, cough symptom score, LCQ, capsaicin cough sensitivity, PHQ-9, MDI, GAD-7 scale, and LES-32 will be evaluated and recorded, and induced sputum supernatant will be collected. During the treatment period, the cough VAS score will be recorded every day, and the questionnaire will be recovered after the treatment. After randomization, the subjects will be followed up by telephone once on the 3rd and 7th days to evaluate and record the patients' cough VAS score, daytime score, nighttime score, CET score and adverse events (AEs). On the 14th, 21st, 28th, 35th, and 42nd days, the patients will return to the center to evaluate and record their cough VAS, daytime score, nighttime score, CET score, LCQ, MDI, GAD-7, LES- 32 and cough frequency, capsaicin cough sensitivity and induced sputum supernatant will be recorded on the 14th and 42nd days.One week after the completion of the treatment period, the patients are followed up again to evaluate and record the cough frequency, cough VAS, daytime score, nighttime score, CET score, LCQ, capsaicin cough sensitivity, PHQ-9, MDI, GAD-7, LES-32, and collect induced sputum supernatant. After the follow-up, the blinding will be unmasked, and the patients in the control group will be treated with duloxetine hydrochloride enteric-coated tablets 20 mg TID (started with 20 mg QD, increased 20 mg daily until 20 mg TID) for 42 days. The schedule of events for the enrolment, interventions and assessments for participants is shown in Fig. The flow of patients through the study. VAS, visual analog scale; LCQ, Leicester Cough Questionnaire; CET, cough evaluation test; PHQ-9, Patient Health Questionnaire-9; MDI, Major Depression Inventory; GAD-7, the Generalized Anxiety Disorder-7 scale; LES-32, Life Events ScaleOutline of planned visitNotes: 